Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections
Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy Mucinex (2400 mg/d) and Immediate-Release Guaifenesin (800 mg/d) in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections For 7 Days
Sponsor: Reckitt Benckiser LLC
A PHASE2/PHASE3 clinical study on Acute Upper Respiratory Tract Infection, this trial is completed. The trial is conducted by Reckitt Benckiser LLC and has accumulated 6 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Reckitt Benckiser LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Austin, United States , Bell Gardens, United States , Bellevue, United States , Brighton, United States , Carrollton, United States , Chicago, United States , Cincinnati, United States , Colorado Springs, United States , Dakota Dunes, United States , Daytona Beach, United States and 31 more locations